IQ-AI Limited (GB:IQAI) has released an update.
IQ-AI Limited’s subsidiary, Imaging Biometrics, LLC, has announced that its mobile app, IB Nimble, will be adopted by a major East Coast cancer center to enhance the treatment of brain metastases. The app facilitates timely, collaborative discussions among specialists, aiming to improve patient care outcomes and streamline treatment planning. Upcoming enhancements to the software, including a feature for viewing medical images, are expected to further boost its utility in multi-site medical collaborations.
For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.
